Santosha Vardhana, MD, PhD

Elucidating the mechanisms of response and resistance to bispecific antibody therapies in indolent B-cell non-Hodgkin lymphomas

Bispecific antibodies, which have emerged as a potent treatment for patients with B-cell lymphomas, activate immune-mediated killing of cancer cells. The proposed research will determine the cellular actors that drive initial and sustained responses to this novel class of therapeutics and identify targetable resistance mechanisms to prevent relapse following treatment.